BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

118 related articles for article (PubMed ID: 32952072)

  • 1. Carcinoembryonic Antigen-related Tumor Kinetics After Eight Weeks of Chemotherapy is Independently Associated With Overall Survival in Patients With Metastatic Colorectal Cancer.
    Colloca GA; Venturino A; Guarneri D
    Clin Colorectal Cancer; 2020 Dec; 19(4):e200-e207. PubMed ID: 32952072
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A retrospective cohort study of metastatic colorectal cancer patients treated with oxaliplatin-based chemotherapy, with an exploratory analysis of changing serum carcinoembryonic antigen levels.
    Ng SL; Burns WI; Snyder RD; Newnham GM; McLachlan SA; Liew D; Dowling AJ
    Asia Pac J Clin Oncol; 2012 Jun; 8(2):172-9. PubMed ID: 22524576
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Baseline carcinoembryonic antigen (CEA) serum levels predict bevacizumab-based treatment response in metastatic colorectal cancer.
    Prager GW; Braemswig KH; Martel A; Unseld M; Heinze G; Brodowicz T; Scheithauer W; Kornek G; Zielinski CC
    Cancer Sci; 2014 Aug; 105(8):996-1001. PubMed ID: 24850362
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Concordance of Carcinoembryonic Antigen Ratio and Response Evaluation Criteria in Solid Tumors as Prognostic Surrogate Indicators of Metastatic Colorectal Cancer Patients Treated with Chemotherapy.
    Huang SC; Lin JK; Lin TC; Chen WS; Yang SH; Wang HS; Lan YT; Lin CC; Jiang JK; Chang SC
    Ann Surg Oncol; 2015 Jul; 22(7):2262-8. PubMed ID: 25586242
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Relevance of baseline carcinoembryonic antigen for first-line treatment against metastatic colorectal cancer with FOLFIRI plus cetuximab or bevacizumab (FIRE-3 trial).
    Holch JW; Ricard I; Stintzing S; Fischer von Weikersthal L; Decker T; Kiani A; Vehling-Kaiser U; Heintges T; Kahl C; Kullmann F; Scheithauer W; Moehler M; Jelas I; Modest DP; Westphalen CB; von Einem JC; Michl M; Heinemann V
    Eur J Cancer; 2019 Jan; 106():115-125. PubMed ID: 30496943
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Prognostic and predictive value of VEGF, sVEGFR-2 and CEA in mCRC studies comparing cediranib, bevacizumab and chemotherapy.
    Jürgensmeier JM; Schmoll HJ; Robertson JD; Brooks L; Taboada M; Morgan SR; Wilson D; Hoff PM
    Br J Cancer; 2013 Apr; 108(6):1316-23. PubMed ID: 23449351
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The dynamic monitoring of CEA in response to chemotherapy and prognosis of mCRC patients.
    Yu P; Zhou M; Qu J; Fu L; Li X; Cai R; Jin B; Teng Y; Liu J; Shi J; Zhang J
    BMC Cancer; 2018 Nov; 18(1):1076. PubMed ID: 30404612
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The impact of carcinoembryonic antigen flare in patients with advanced colorectal cancer receiving first-line chemotherapy.
    Strimpakos AS; Cunningham D; Mikropoulos C; Petkar I; Barbachano Y; Chau I
    Ann Oncol; 2010 May; 21(5):1013-9. PubMed ID: 19861580
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Evaluation of predictive markers for patients with advanced colorectal cancer.
    Byström P; Berglund Å; Nygren P; Wernroth L; Johansson B; Larsson A; Glimelius B
    Acta Oncol; 2012 Sep; 51(7):849-59. PubMed ID: 22974092
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Gamma-glutamyl transpeptidase level is a novel adverse prognostic indicator in human metastatic colorectal cancer.
    He WZ; Guo GF; Yin CX; Jiang C; Wang F; Qiu HJ; Chen XX; Rong RM; Zhang B; Xia LP
    Colorectal Dis; 2013 Aug; 15(8):e443-52. PubMed ID: 23621885
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Clinical significance of changes in systemic inflammatory markers and carcinoembryonic antigen levels in predicting metastatic colorectal cancer prognosis and chemotherapy response.
    Kim IH; Lee JE; Yang JH; Jeong JW; Ro S; Lee MA
    Asia Pac J Clin Oncol; 2018 Jun; 14(3):239-246. PubMed ID: 29044941
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Preoperative Serum Carcinoembryonic Antigen Level as a Prognostic Factor for Recurrence and Survival After Curative Resection Followed by Adjuvant Chemotherapy in Stage III Colon Cancer.
    Kim CG; Ahn JB; Jung M; Beom SH; Heo SJ; Kim JH; Kim YJ; Kim NK; Min BS; Koom WS; Kim H; Roh YH; Ma BG; Shin SJ
    Ann Surg Oncol; 2017 Jan; 24(1):227-235. PubMed ID: 27699609
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Clinico-pathological correlation of serial measurement of circulating tumor cells in 24 metastatic colorectal cancer patients receiving chemotherapy reveals interpatient heterogeneity correlated with CEA levels but independent of KRAS and BRAF mutation.
    Das A; Kunkel M; Joudeh J; Dicker DT; Scicchitano A; Allen JE; Sarwani N; Yang Z; Kaifi J; Zhu J; Liao J; El-Deiry WS
    Cancer Biol Ther; 2015; 16(5):709-13. PubMed ID: 25806877
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The Association of Serum Carcinoembryonic Antigen, Carbohydrate Antigen 19-9, Thymidine Kinase, and Tissue Polypeptide Specific Antigen with Outcomes of Patients with Metastatic Colorectal Cancer Treated with Bevacizumab: a Retrospective Study.
    Fiala O; Finek J; Buchler T; Matejka VM; Holubec L; Kulhankova J; Bortlicek Z; Liska V; Topolcan O
    Target Oncol; 2015 Dec; 10(4):549-55. PubMed ID: 25875421
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Elevated CA19-9 as the most significant prognostic factor in advanced colorectal carcinoma.
    Kouri M; Pyrhönen S; Kuusela P
    J Surg Oncol; 1992 Feb; 49(2):78-85. PubMed ID: 1738240
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Clinical significance of a transient increase in carcinoembryonic antigen and carbohydrate antigen 19-9 in patients with metastatic colorectal cancer receiving chemotherapy].
    Li YH; An X; Xiang XJ; Wang ZQ; Wang FH; Feng F; Jiang WQ; He YJ; Xu RH
    Ai Zheng; 2009 Sep; 28(9):939-44. PubMed ID: 19728911
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Clinical Significance of Discordance between Carcinoembryonic Antigen Levels and RECIST in Metastatic Colorectal Cancer.
    Kim IH; Lee JE; Yang JH; Jeong JW; Ro S; Oh ST; Kim JG; Choi MH; Lee MA
    Cancer Res Treat; 2018 Jan; 50(1):283-292. PubMed ID: 28494536
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Relationship among circulating tumor cells, CEA and overall survival in patients with metastatic colorectal cancer.
    Aggarwal C; Meropol NJ; Punt CJ; Iannotti N; Saidman BH; Sabbath KD; Gabrail NY; Picus J; Morse MA; Mitchell E; Miller MC; Cohen SJ
    Ann Oncol; 2013 Feb; 24(2):420-428. PubMed ID: 23028040
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Can carcinoembryonic antigen replace computed tomography in response evaluation of metastatic colorectal cancer?
    Hermunen K; Lantto E; Poussa T; Haglund C; Österlund P
    Acta Oncol; 2018 Jun; 57(6):750-758. PubMed ID: 29388498
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Prognostic factors associated with primary cancer in curatively resected stage IV colorectal cancer.
    Huh JW; Lee WY; Park YA; Cho YB; Yun SH; Kim HC; Chun HK
    J Cancer Res Clin Oncol; 2014 Mar; 140(3):435-41. PubMed ID: 24414039
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.